Drug Search Results
More Filters [+]

HB-101

Alternative Names: hb-101, hb101, hb 101
Latest Update: 2024-06-10
Latest Update Note: PubMed Publication

Product Description

HB-101 is a bivalent recombinant vaccine against human CMV infection.

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hookipa Biotech
Company Location: NEW YORK NY 10016
Company CEO: Joern Aldag
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HB-101

Countries in Clinic: Denmark, France, Germany, Norway, United Kingdom, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Cytomegalovirus Infections|Kidney Transplant

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

H-100-002

P2

Completed

Cytomegalovirus Infections|Kidney Transplant

2022-06-22

2017-005047-32

P2

Completed

Kidney Transplant

2022-06-22

Recent News Events